Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

Reham Abdel-Wahab, Gauri R. Varadhachary, Priya R. Bhosale, Xuemei Wang, David R. Fogelman, Rachna T. Shroff, Michael J. Overman, Robert A. Wolff, Milind Javle

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences